Results 31 to 40 of about 115,232 (278)

PCC0208018 exerts antitumor effects by activating effector T cells

International Journal of Immunopathology and Pharmacology, 2019
Poor prognosis is associated with melanoma due to immunosuppression profiles, suggesting that immune alterations have an important role in the occurrence, growth, and metastasis of melanoma.
Minmin Ge, Zhengping Hu, Xiao Chen, Guangying Du, Hongbo Wang, Rumeng Liu, Liang Ye, Jingwei Tian   +7 more
doaj   +1 more source

Compartmentalized megakaryocyte death generates functional platelets committed to caspase-independent death [PDF]

, 2003
Caspase-directed apoptosis usually fragments cells, releasing nonfunctional, prothrombogenic, membrane-bound apoptotic bodies marked for rapid engulfment by macrophages.
Jones, David B., Simon B. Brown, Brown, Simon B, Murray C.H. Clarke, David B. Jones, Savill, John, Brendon S. Noble, Clarke, Murray C H, Noble, Brendon S, John Savill   +9 more
core   +1 more source

Staurosporine induces necroptotic cell death under caspase-compromised conditions in U937 cells

, 2012
For a long time necrosis was thought to be an uncontrolled process but evidences recently have revealed that necrosis can also occur in a regulated manner.
Gabor Barna (146087), Pal I Bauer, Istvan Petak, Mihalik, Rudolf, Zsuzsanna A Dunai, Gergely Imre, Istvan Petak (5648680), Pal I. Bauer (144904), Gergely Imre (146083), Imre, Gergely, Tamas Korcsmaros, Dunai, Zsuzsanna A., Barna, Gabor, Rudolf Mihalik, Bauer, Pal I., Gabor Barna, Rudolf Mihalik (146097), Petak, Istvan, Zsuzsanna A. Dunai (144901), Korcsmaros, Tamas, Tamas Korcsmaros (146091)   +20 more
core   +1 more source

Regulation of cell death in cancer - possible implications for immunotherapy

, 2013
Since most anticancer therapies including immunotherapy trigger programmed cell death in cancer cells, defective cell death programs can lead to treatment resistance and tumor immune escape.
Simone Fulda, Simone eFulda, Fulda, Simone   +2 more
core   +1 more source

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer

Therapeutic Advances in Medical Oncology, 2021
Background: Resistance or even hyper-progression to immune checkpoint inhibitors (ICIs) manifesting as accelerated disease progression or death has impeded the clinical use of ICIs.
Teng Li, Han Wang, Jiachen Xu, Chengcheng Li, Yudong Zhang, Guoqiang Wang, Yutao Liu, Shangli Cai, Wenfeng Fang, Junling Li, Zhijie Wang   +10 more
doaj   +1 more source

Soluble interleukin-2 receptor as a predictive and prognostic marker for patients with familial breast cancer

Science Progress, 2021
The incidence of breast cancer increases annually, and it has become common within families of breast cancer patients. Interleukin-2 activates cytotoxic T lymphocytes, which are important for cancer immunity.
Kenji Gonda, Shoichiro Horita, Yuko Maejima, Seiichi Takenoshita, Kenju Shimomura   +4 more
doaj   +1 more source

Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in BRAF V600E-mutated metastatic colorectal cancer: GI-SCREEN post-hoc analysis

ESMO Gastrointestinal Oncology, 2023
Background: The programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1)/programmed cell death-ligand 2 (PD-L2) axis is responsible for cancer immune escape, which facilitates disease progression. However, the role of PD-L1 and PD-L2
M. Imai, Y. Nakamura, T. Denda, Y. Komatsu, S. Yuki, T. Nishina, Y. Hamamoto, H. Hara, T. Esaki, H. Kawakami, K. Kato, T. Satoh, N. Okano, Y. Sunakawa, H. Taniguchi, K. Yamaguchi, T. Yamada, I. Miki, M. Wakabayashi, T. Kuwata, K. Shitara, T. Yoshino   +21 more
doaj   +1 more source

Organizing the interface—Plasma membrane architecture and receptor dynamics in virus‐cell interactions

FEBS Letters, EarlyView.
Plasma membranes contain dynamic nanoscale domains that organize lipids and receptors. Because viruses operate at similar scales, this architecture shapes early infection steps, including attachment, receptor engagement, and entry. Using influenza A virus and HIV‐1 as examples, we highlight how receptor nanoclusters, multivalent glycan interactions ...
Jan Schlegel, Christian Sieben
wiley   +1 more source

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction

Scientific Reports, 2022
Targeting the programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) axis with monoclonal antibodies (mAbs) represents a crucial breakthrough in anticancer therapy, but mAbs are limited by their poor oral bioavailability, adverse ...
Chih-Hao Lu, Wei-Min Chung, Chun-Hao Tsai, Ju-Chien Cheng, Kai-Cheng Hsu, Huey-En Tzeng   +5 more
doaj   +1 more source

Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma

口腔疾病防治, 2021
Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor that seriously threatens human health and life. With increasing studies on the mechanism of tumor immune escape, programmed death receptor 1 (PD-1) and programmed death ligand ...
ZENG Fei, LU Jie, SUN Renhao, FANG Yikang, YU Wenyi, YANG Fang, ZHAO Lu   +6 more
doaj   +1 more source